MediStim

Medistim reports a record revenue of 202 million NOK in Q2 2026 (currency-adjusted +27.5%) and a record EBIT of 65.3 million NOK with an EBIT margin of 32.3%. Half-year revenue exceeded 400 million NOK for the first time; the Americas was the strongest market with currency-adjusted growth of 46.3%. Management sees accelerated growth and further margin expansion, plans product launches in 2027 and quarterly dividends. The stock rose about 5.6% in early trading to $246. » More on de.investing.com

Medistim reports Q3 2025 revenue of 166.8 MNOK (+25.7%) and EBIT of 40.6 MNOK (+27.1%). Results for the year to end‑September show 517.5 MNOK in revenue (+25.8%) and 153.9 MNOK in EBIT (+46.2%); earnings per share rose to 1.90 NOK (+48.4%). Gross margin improved to 81.5% and operating cash flow more than doubled to 69.088 MNOK, supported by growth in all regions, especially EMEA. Management plans to expand US presence, the Medistim Academy and recurring revenues, but sees risks from market saturation, health budgets and competitive pressure. » More on de.investing.com

Medistim ASA recorded 16.7% revenue growth and a 31% increase in operating profit in the second quarter of 2025, sending the share price up 14.35% and trading close to its 52-week high. Growth was driven mainly by the Americas and the Asia-Pacific region, while EMEA saw a slight decline; the company is advancing product innovations, AI-powered software development and market expansion. Management cites a strategic focus on combined flow and imaging systems, possible pricing measures and is evaluating further software rollouts. » More on de.investing.com